Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success

The Phase III failure of the Alzheimer’s treatment was largely expected, but is nonetheless a disappointment for the disease and for the anti-amyloid field, casting a shadow over other therapies in development, including Lilly’s own pipeline.